



NIH funding opportunities



Faculty of Medicine and Health Sciences: Research Development and Support

31 Aug 2020 (#39)

[Click on blue [hyperlink](#) for further information]

The NIH funding opportunities listed below are only a **selection** of pre-screened, currently open health funding opportunities for which **South African institutions are eligible to apply**. For a comprehensive selection of NIH funding opportunities, please visit www.grants.nih.gov or www.sun.ac.za/RDSfunding (current & archive).

Confirm your intent to apply ASAP, but not later than 60 days before the submission date.

Tygerberg Campus: cdevries@sun.ac.za • Stellenbosch Campus lizek@sun.ac.za

Important Notices

NOT-TW-20-007: Notice of NIH Participation in the Ecology and Evolution of Infectious Diseases Program. The purpose of this Notice is to announce that the NIH is collaborating on the multi-agency funding opportunity, the Ecology and Evolution of Infectious Diseases (EEID) ([NSF-20-585](#)). The central theme of submitted projects must be the quantitative or computational understanding of pathogen transmission dynamics. The intent is discovery of principles of infectious disease transmission and testing mathematical or computational models that elucidate infectious disease systems. Projects should be broad, interdisciplinary efforts that go beyond the scope of typical studies. They should focus on the determinants and interactions of transmission among any host species, including but not limited to humans, non-human animals, and/or plants. **Applications for research on disease systems of public health concern to Low- and Middle-Income Countries (LMICs) are strongly encouraged**, as are disease systems of concern in agricultural systems. Investigators are encouraged to develop the appropriate multidisciplinary team, including for example, anthropologists, modelers, ecologists, bioinformaticians, genomics researchers, social scientists, economists, oceanographers, mathematical scientists, epidemiologists, evolutionary biologists, entomologists, parasitologists, microbiologists, bacteriologists, virologists, pathologists or veterinarians, with the goal of integrating knowledge across disciplines to enhance our ability to predict and control infectious diseases. Applications must be submitted to the NSF in accordance with NSF-20-585, and not to the NIH. Following a jointly-conducted initial peer review of these applications, meritorious applications may be recommended for funding by either NSF, NIH, or USDA, at the option of the agencies. For those applications that are selected for funding by participating NIH Institutes and Centers, the PD/PI will be invited to submit the application in an NIH-approved format directly to the Center for Scientific Review (<http://www.csr.nih.gov/>). Potential applicants are strongly encouraged to contact NIH or NSF program officials prior to submitting an application. The deadline for submission to NSF is 18 November 2020. Direct all inquiries to: Christine Jessup, Ph.D. Fogarty International Center ([FIC](#)) Email: Christine.Jessup@nih.gov and Stephanie Coomes, Ph.D. National Institute of Allergy and Infectious Diseases ([NIAID](#)) Email: stephanie.coomes@nih.gov

Upcoming Deadlines

- [Harnessing Data Science for Health Discovery and Innovation in Africa \(DS-I Africa\)](#):
Research Training Program due date: 24 November 2020
Ethical, Legal, and Social Implications Research due date: 1 December 2020
Open Data Science Platform and Coordinating Center due date: 3 December 2020
Research Hubs non-AIDS application due date: 8 December 2020
Research Hubs AIDS application due date: 8 February 2021
- [Mobile Health: Technology and Outcomes in LMICs](#) 24 September 2020; AIDS deadline 3 December 2020
- [Emerging Global Leader Award](#) 4 November 2020
- [Global Brain Disorders Research](#) 6 November 2020
- [Reducing Stigma to Improve HIV/AIDS Prevention, Treatment and Care in LMICs](#) 12 November 2020

- [Chronic, Noncommunicable Diseases and Disorders Research Training \(NCD-Lifespan\)](#) D43 13 November 2020
- [Ecology and Evolution of Infectious Diseases Initiative \(EEID\)](#) 18 November 2020

Parent Announcements

Parent Announcements (PA) for unsolicited are broad funding opportunity announcements allowing applicants to submit investigator-initiated applications. They are open for up to 3 years and use standard due dates.

- [PA-20-185](#) NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed)
- [PA-20-184](#) Research Project Grant (Parent R01 Basic Experimental Studies with Humans Required)
- [PA-20-183](#) Research Project Grant (Parent R01 Clinical Trial Required)
- [PA-20-200](#) NIH Small Research Grant Program (Parent R03 Clinical Trial Not Allowed)
- [PA-20-195](#) NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Not Allowed)
- [PA-20-194](#) NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Required)
- [PA-20-196](#) NIH Exploratory/Developmental Research Grant Program (Parent R21 Basic Experimental Studies with Humans Required)

Funding Opportunities

1. New Models of Integrated HIV/AIDS, Addiction, and Primary Care Services (R01 Clinical Trial Required)		
Letter of Intent: 30 days prior to the application due date	Hyperlink: PAR-20-273	Type: R01
Application Due Date: November 18, 2020, August 11, 2021, November 18, 2021, August 11, 2022, November 18, 2022, August 11, 2023. Apply by 5:00 PM local time of applicant organization.		
Funding Opportunity Announcement: The purpose of this FOA is to support the testing of enhanced models of care that optimally integrate HIV, addiction, and primary care services. NIDA is interested in research that addresses gaps related to the delivery of comprehensive, integrated health services to include the full continuum of HIV/AIDS services, addiction prevention and treatment services, and primary care services, with a goal of improving the coordination of care, and improving health outcomes related to HIV and SUD in the US.		
Budget: NIDA expects to fund a total of \$1.5M in new awards in FY21 across both the R01 and R34 mechanisms. Future year amounts will depend on annual appropriations. Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years.		

2. New Models of Integrated HIV/AIDS, Addiction, and Primary Care Services (R34 Clinical Trial Required)		
Letter of Intent: 30 days prior to the application due date	Hyperlink: PAR-20-274	Type: R34
Application Due Date: November 18, 2020, August 11, 2021, November 18, 2021, August 11, 2022, November 18, 2022, August 11, 2023. Apply by 5:00 PM local time of applicant organization.		
Funding Opportunity Announcement: This funding opportunity announcement will support the development and testing of enhanced models of care that are able to optimally integrate HIV, addiction, and primary care services. NIDA is interested in research that addresses gaps related to the delivery of comprehensive, integrated health services to include the full continuum of HIV/AIDS services, addiction prevention and treatment services, and primary care services, with a goal of improving the coordination of care, and improving health outcomes related to HIV and SUD in the US.		
Budget: NIDA expects to fund a total of \$1.5M in new awards in FY21 across the both the R34 and R01 mechanisms. Future year amounts will depend on annual appropriations. Direct costs are limited to \$450,000 over the 3-year R34 project period, with no more than \$225,000 in direct costs allowed in any single year. The scope of the proposed project should determine the project period. The maximum project period is 3 years.		

3. NCI Clinical and Translational Exploratory/Developmental Studies (R21 Clinical Trial Optional)		
Letter of Intent: 30 days prior to the application due date	Hyperlink: PAR-20-292	Type: R21
Application Due Date: October 20, 2020; February 19, 2021; June 21, 2021; October 20, 2021; February 22, 2022; June 21, 2022. AIDS dates: December 18, 2020; March 19, 2021; July 20, 2021; December 17, 2021; March 21, 2022; July 20, 2022. Apply by 5:00 PM local time of applicant organization.		
Funding Opportunity Announcement: This Funding Opportunity Announcement (FOA) supports preclinical and early phase clinical research, as well as correlative studies, directly related to advancements in cancer treatment, diagnosis, prevention, symptom management, or reduction of cancer health disparities. This includes (but is not limited to) development and testing of the following: new molecular agents or biologics for cancer treatment; management strategies for cancer-related symptoms or treatment-related toxicity; cancer screening or diagnostic tools, such as imaging techniques; cancer preventive agents or approaches; predictive and prognostic biomarkers for patient selection or stratification; clinically relevant in vivo or in vitro tumor models (including genetically engineered mouse models, patient-derived xenograft models, organoids, and cell lines); and strategies to address therapeutic outcome disparities among diverse racial/ethnic populations. In addition to novel agents, new treatment strategies may involve repurposed agents or novel combinations of interventions (including radiation), based on established mechanisms of action. Comparative oncology studies in dogs investigating strategies for treatment and diagnosis of human disease are supported as well. This FOA does not support research that focuses on basic cancer biology (such as studies of cancer-related pathways or molecular mechanisms), late-stage clinical trials, risk assessment studies, epidemiological studies, or studies of behavioral interventions. These applications will be deemed not responsive to this FOA and will not be reviewed (see below for a more detailed description of studies that are not responsive for this FOA). The R21 mechanism is intended to encourage exploratory and developmental research projects by providing		

support for the early and conceptual stages of these projects. These studies may involve considerable risk but may lead to breakthroughs in particular areas, or to the development of novel techniques, agents, methodologies, models, or applications that could have a major impact on cancer research (preclinical or clinical).

Budget: The combined budget for direct costs for the two-year project period may not exceed \$275,000. No more than \$200,000 may be requested in any single year.

4. Clinical Translation of Activated Optical Fluorescence Methods and Technologies for Sensitive Cancer Detection in Vivo (R01 Clinical Trial Optional)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [PAR-20-295](#)

Type: R01

Application Due Date: February 10, 2021; October 13, 2021. Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: The purpose of this Funding Opportunity Announcement (FOA) is to bring a highly sensitive imaging technology capable of detecting very small (1-3 mm³) tumors in vivo to clinical utility. Through this FOA, the National Cancer Institute (NCI) solicits innovative concepts that propose a path to clinical validation for in vivo 'intelligent' or activated optical fluorescence agents or probes with previously demonstrated capabilities for the detection of small tumors. Current imaging techniques are in use for non-invasive cancer detection, but clinical methods are limited to detecting masses several millimeters to centimeters in size. To image small primary or metastatic tumor sites composed of 10⁶ -10⁷ cells, imaging sensitivity must be improved. This can be achieved without significant hardware advances by improving the contrast between diseased and healthy tissue captured in the image. Thus, there is a clinical need for techniques that improve image contrast between tumors and surrounding normal tissue. There are several novel optical fluorescence methods that rely on the use of specialized agents that are activated when coupled to a tumor target. These activated agents dramatically increase the contrast between small tumor cell masses and surrounding tissue. Efforts to develop activated fluorescence imaging agents have been ongoing for over a decade. These developmental successes now need to be translated for clinical use. This FOA thus supports translation of novel activated optical fluorescence agents for sensitive cancer detection in vivo. Clinical translation and validation should be the primary goals of the proposed research. The bulk of the proposed research must focus on translating improvements in imaging sensitivity to a clinical environment with the goal of demonstrating that tumor cell aggregates on the order of 1 mm³ in volume can be visualized in vivo. However, minimal research toward development of the probe in preparation for clinical validation will be accepted under this FOA. This FOA thus supports translation of already developed technologies for small tumor detection in vivo. It is not intended to support continued development of novel agents or preclinical studies.

Budget: Application budgets may not exceed \$500,000/year (in direct costs). The maximum project period is up to 5 years.

5. NCI Pediatric In Vivo Testing Program (U01 Clinical Trial Not Allowed)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [RFA-CA-20-034](#)

Type: U01

Application Due Date: November 09, 2020. Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: This Funding Opportunity Announcement (FOA) is for Research Teams to form the NCI Pediatric in Vivo Testing Program (henceforth termed the Ped-In Vivo-TP). The Research Teams of the Ped-In Vivo-TP will determine the activity of pediatric anticancer drug candidates using preclinical models relevant to the cancer(s) on which their team focuses (supported under this FOA) and will work in concert with the Ped-In Vivo-TP Coordinating Center (supported under RFA-CA-20-041). The Research Teams will use genomically characterized pediatric cancer models to develop a rigorous preclinical testing program that will generate reliable data that can be used to inform new agent prioritization decisions for childhood cancer clinical testing. The Ped-In Vivo-TP is envisioned as a way for NCI to support the Foundation for the National Institutes of Health (FNIH)-organized Public-Private Partnership (PPP) for pediatric preclinical testing. The PPP is being developed to accelerate the pace and to broaden the scope of pediatric preclinical testing of agents being developed for adult cancer indications. Pharmaceutical companies and representatives of regulatory agencies will also participate in the PPP. This FOA invites applications from Research Teams that have developed panels of genomically characterized pediatric cancer models and that have the capacity for using their panels to test up to 8-10 agents per year. The Ped-In Vivo-TP Awardees will work closely with the Ped-In Vivo-TP Coordinating Center in the testing of agents and in the analysis and reporting of testing results.

Budget: NCI intends to commit approximately \$5.1 million to fund up to 8 awards in FY 2021. The application budget is limited to \$450,000 in direct costs per year and should reflect the actual needs of the project. The maximum project period is 5 years.

6. Toward Elucidating Mechanisms of HIV Pathogenesis within the Mission of the NIDDK (Pathogenesis TEAMS) (R01 Clinical Trial Optional)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [RFA-DK-20-022](#)

Type: R01

Application Due Date: March 3, 2021 and November 17, 2021. Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: The purpose of this Funding Opportunity Announcement (FOA) is to support multidisciplinary research teams with complementary expertise in HIV and pathobiology, pathophysiology, and/or metabolism in organs, tissues, and/or biological systems of specific interest to the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). These teams will comprehensively interrogate fundamental mechanisms underlying HIV-associated comorbidities, coinfections, and complications relevant to the mission of the NIDDK and advance progress toward alleviating them.

Budget: NIDDK intends to commit \$3,000,000 in FY 2022 to fund 4-6 awards. Application budgets are limited to \$500,000 direct costs per year and should reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years.

Research Development and Support Division (RDSD),
Faculty of Medicine and Health Sciences, Stellenbosch University
5th Floor, Teaching Block, Tygerberg Campus.
Enquiries: Christa
e: cdevries@sun.ac.za | t: +27 21 938 9838

Afdeling Navorsingsontwikkeling/Division for Research Development (DRD)
Stellenbosch University
2038 Wilcocks Building, Ryneveld Street
Enquiries: Lizel
e: lizelk@sun.ac.za | t: +27 21 808 2105